• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology

Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology

 

 

STEPHEN J. WILLIAMS, Ph.D.

Tel: 215 487 0259 (h)

610 331 1016 (c)

Email: sjwilliamspa@comcast.net

UPDATED on 11/9/2020

 

  1. Co-Editor Series D, Volume 4:

    Human Reproductive System, Genomic Endocrinology and Cancer Types

    http://www.amazon.com/dp/B08VTFWVKM

    Available on Amazon.com since 2/2/2021

  2. NLP with INTERNS – Proof of Concept – on–going
  3. WIKIPEDIA ENTRY for LPBI & Aviva – REFERENCE GENERATION by 3rd party
  4. AI in Genomics & Cancer – Development of the PORTAL
  5. Interface with Blockchain vendor and NLP two vendors

Personal Bio

Personal Statement: My scientific career has centered on understanding the mechanisms underlying initiation of cancer, as well as the pharmacologic and toxicologic basis of chemotherapy. My research has focused on modeling the etiology and metabolic alterations of human ovarian cancer and malignant mesothelioma, using cellular, molecular and in-vivo strategies.  Current research focuses on growth factor cell signaling in mesothelioma. Altogether, my research goals have concentrated on the cellular stresses, and the resultant genetic and metabolic alterations which provide not only a fertile micro-environment for oncogenesis, tumor progression and disease etiology but also an opportunity for therapeutic development

 

Biography: For the onset of my scientific career I entered one of the first undergraduate toxicology programs in the country, at the Philadelphia College of Pharmacy & Science, and trained in various methodologies in toxicology and pharmacology, including research into effects of leukotrienes and leukotriene antagonists on  gastrointestinal motility. I continued with my research training at the University of Pennsylvania Institute for Environmental Medicine, studying the effects of hyperbaric oxygen, and free radicals on lung function and the pathology of Sudden Infant Death Syndrome.  I subsequently received my PhD in Pharmacology from Temple University, with my thesis, under Dr. Michael Sirover, involving the biochemical and pharmacologic effects on noncanonical protein functions in metabolism and DNA repair. Afterward, I continued with postdoctoral training in the Department of Pharmacology under an NCI-PRAT fellowship and in the Ovarian Cancer Program in the laboratory of Dr. Thomas Hamilton.  My research involved determination of mechanisms of cisplatin resistance in ovarian cancer, discovering genes causal in early ovarian oncogenesis, and development of animal ovarian tumor models useful for determining ovarian cancer driver genes, determining chemotherapeutic efficacy, and development of imaging and surrogate tumor biomarker methods for detection of ovarian tumor burden in in-vivo ovarian cancer models.  To this end, I developed one of the first, and patented, porcine ovarian tumor models, and with colleagues, additional models to measure intraperitoneal ovarian cancer using both surrogate tumor markers and MRI imaging methodology useful for chemotherapeutic evaluation.

As scientific research and information was entering a new explosive age of massive data, I decided to assist Dr. Aviva Lev Ari in her venture Leaders in Pharmaceutical Business Intelligence, in developing a methodology of scientific curation, in collaboration with Dr. Larry Bernstein and a worldwide network of expert scientists and clinicians.   This effort culminated in the development of an influential web 2.0 platform for the curation, organization, and dissemination of scientific and biomedical findings in addition of the creation of 16 medical e-books on multiple topics.  As such I became senior editor on two volumes, an e-book series on Cancer and a series on Genomics.

Concurrently I was designated an adjunct professor in Temple University College of Science & Technology, teaching a course on Cell Signaling and Cancer Biology, as well as an associate professor in the Sbarro Health Research Organization where I head the grants department including grants management and administration.  Currently I also decided to continue my research efforts into understanding events causal in early oncogenesis and joined the research organization ISOPROG, where we have been researching autocrine growth factor loops involved in the malignant phenotype in mesothelioma and other cancer types.

As a result of the aforementioned endeavors, I have multiple peer-reviewed publications and book chapters as well as whole books in the fields of cancer, genomics, and personalized oncology.  In addition, I am a frequent reviewer for such journals such as Cancer Research, Cancers, the Journal of Cellular Physiology, and others.  I am a member of the AAAS, AACR, Mid Atlantic Pharmacology and Mid Atlantic Toxicology Society.

AREAS OF EXPERTISE     

  • Molecular Biology and Biochemistry: Transitional research, recombinant DNA technologies; RNA/DNA purification and analysis; real-time PCR and primer design; DNA methylation; Western analysis (quantative); ELISA; DNA repair assays; enzyme kinetics; analysis of cellular redox status; protein modification; enzyme and protein purification; column chromatography; HPLC; immunohistochemistry; reporter gene assays.
  • Cellular: Primary cell culture and isolation; development and establishment of cell lines (primary and tumorigenic, stable lines generation); flow cytometry; Guava single cell analysis; soft agar colony assay; cell proliferation/toxicity assays; in-vitro transformation.
  • In-Vivo: Small animal handling and colony maintenance; development of animal models of ovarian cancer; in-vivo preclinical drug evaluation; necropsy and gross pathology; small animal imaging.

Curriculum Vitae

SCIENCE Side Member 

Responsibilities @LPBI:

(1) Curator initiated new content creation

(2) Updates to own published articles in the Journal

(3) Commissions by the Editor-in-Chief – One curation per WEEK

(4) Client facing engagement with External relations

(5) Advice for the Founder

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/

(1)    TNS #1: https://www.wolfram.com/featureset/machine-learning/

1.1   LPBI LEAD on Comparison of NLP results obtained for Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language

1.2   LPBI LEAD on Application on the ingress TEXT from: Cancer Volume 1 &2 and Genomics Volume 1&2 

1.3   LPBI LEAD on Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:

  • The Wolfram Solution for Biological Sciences
  • The Wolfram Data Drop is an open service that makes it easy to accumulate data of any kind, from anywhere—setting it up for immediate computation, visualization, analysis, querying, or other operations

(2)    TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End

(3)    Co-Editor LPBI Group’s BioMed Book #17 – COMPLETE Editorials by 12/10/2020

 

Publications with Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Series A: e-Books on Cardiovascular Diseases

Volume One: Perspectives on Nitric Oxide

Sr. Editor: Larry Bernstein, MD, FCAP, Editor: Aviral Vatsa, PhD and Content Consultant: Stephen J Williams, PhD

http://www.amazon.com/dp/B00DINFFYC

 

Series C: e-Books on Cancer & Oncology

Volume 1:

Cancer Biology and Genomics for Disease Diagnosis

http://www.amazon.com/dp/B013RVYR2K 

Volume 2:

Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

http://www.amazon.com/dp/B071VQ6YYK 

 

Series B: Frontiers in Genomics Research

Volume 1: 

Genomics Orientations for Personalized Medicine

http://www.amazon.com/dp/B018DHBUO6

Volume 2:

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B08385KF87

 

PUBLICATIONS in Open Access Online Scientific Journal

https://pharmaceuticalintelligence.com/

Cancer

 

Williams, S.J. July 1, 2014. Good and Bad News Reported for Ovarian Cancer Therapy

https://pharmaceuticalintelligence.com/2014/07/01/good-and-bad-news-reported-for-ovarian-cancer-therapy-2/

Williams, S.J. June 17, 2014. Can Mobile Health Apps Improve Oral-Chemotherapy Adherence? The Benefit of Gamification.

https://pharmaceuticalintelligence.com/2014/06/17/can-mobile-health-apps-improve-oral-chemotherapy-adherence-the-benefit-of-gamification/

Williams, S.J. June 11, 2014. The SCID Pig II: Researchers Develop Another SCID Pig, And Another Great Model For Cancer Research

https://pharmaceuticalintelligence.com/2014/06/11/the-scid-pig-ii-researchers-develop-another-scid-pig-and-another-great-model-for-cancer-research/

Williams, S.J. May 6, 2014. The Cancer Research Concentration @ Leaders in Pharmaceutical Business Intelligence

https://pharmaceuticalintelligence.com/2014/05/06/the-cancer-concentration-leaders-in-pharmaceutical-business-intelligence/

Williams, S.J. April 4, 2014. Heroes in Medical Research: Developing Models for Cancer Research

https://pharmaceuticalintelligence.com/2014/04/04/heroes-in-medical-research-developing-models-for-cancer-research/

Williams, S.J. January 3, 2014. Loss of Gene Islands May Promote a Cancer Genome’s Evolution: A new Hypothesis on Oncogenesis

https://pharmaceuticalintelligence.com/2014/01/23/loss-of-gene-islands-may-promote-a-cancer-cells-survival-proliferation-and-evolution-a-new-hypothesis-and-second-paper-validating-model-on-oncogenesis-from-the-elledge-laboratory/

Williams, S.J. November 23, 2013. Liver Toxicity halts Clinical Trial of IAP Antagonist for Advanced Solid Tumors

https://pharmaceuticalintelligence.com/2013/11/25/liver-toxicity-halts-clinical-trial-of-iap-antagonist-for-advanced-solid-tumors/

Williams, S.J. October 11, 2014. The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research

https://pharmaceuticalintelligence.com/2013/10/10/the-scid-pig-how-pigs-are-becoming-a-great-alternate-model-for-cancer-research/

Williams, S.J. September 4, 2013. Issues in Personalized Medicine: Discussions of Intratumor Heterogeneity from the Oncology Pharma forum on LinkedIn

https://pharmaceuticalintelligence.com/2013/09/04/issues-in-personalized-medicine-discussions-of-intratumor-heterogeneity-from-the-oncology-pharma-forum-on-linkedin/

Williams, S.J. August 7, 2013. Nitric Oxide Mitigates Sensitivity of Melanoma Cells to Cisplatin  

https://pharmaceuticalintelligence.com/2013/08/07/nitric-oxide-increases-sensitivity-of-melanoma-cells-to-cisplatin/

Williams, S.J. June 13, 2013. Combining Nanotube Technology and Genetically Engineered Antibodies to Detect Prostate Cancer Biomarkers

https://pharmaceuticalintelligence.com/2013/06/13/combining-nanotube-technology-and-genetically-engineered-antibodies-to-detect-prostate-cancer-biomarkers/

Williams, S.J. May 30, 2013. New scheme to routinely test patients for inherited cancer genes

https://pharmaceuticalintelligence.com/2013/05/30/new-scheme-to-routinely-test-patients-for-inherited-cancer-genes/

Williams, S.J. April 17,2013. Heroes in Medical Research: Dr. Robert Ting, Ph.D. and Retrovirus in AIDS and Cancer

https://pharmaceuticalintelligence.com/2013/04/17/heroes-in-medical-research-dr-robert-ting-ph-d-and-retrovirus-in-aids-and-cancer/

Williams, S.J. April 10, 2013. Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

https://pharmaceuticalintelligence.com/2013/04/10/issues-in-personalized-medicine-in-cancer-intratumor-heterogeneity-and-branched-evolution-revealed-by-multiregion-sequencing/

Williams, S.J. March 13, 2013. Personalized Medicine: Clinical Aspiration of Microarrays

https://pharmaceuticalintelligence.com/2013/03/13/personalized-medicine-clinical-aspiration-of-microarrays/

Williams, S.J. March 12, 2013. AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo

https://pharmaceuticalintelligence.com/2013/03/12/ampk-is-a-negative-regulator-of-the-warburg-effect-and-suppresses-tumor-growth-in-vivo/

Williams, S.J. February 10, 2014. Rewriting the Mathematics of Tumor Growth; Teams Use Math Models to Sort Drivers from Passengers

https://pharmaceuticalintelligence.com/2013/02/10/rewriting-the-mathematics-of-tumor-growth-teams-use-math-models-to-sort-drivers-from-passengers/

Williams, S.J. February 3, 2013. Genome-Wide Detection of Single-Nucleotide and Copy-Number Variation of a Single Human Cell

https://pharmaceuticalintelligence.com/2013/02/03/genome-wide-detection-of-single-nucleotide-and-copy-number-variation-of-a-single-human-cell/

Williams, S.J. January 12, 2013. Heroes in Medical Research: Barnett Rosenberg and the Discovery of Cisplatin

https://pharmaceuticalintelligence.com/2013/01/12/heroes-in-medical-research-barnett-rosenberg-and-the-discovery-of-cisplatin/

Williams, S.J. January 3, 2013. Differentiation Therapy – Epigenetics Tackles Solid Tumors

https://pharmaceuticalintelligence.com/2013/01/03/differentiation-therapy-epigenetics-tackles-solid-tumors/

Williams, S.J. November 30, 2012. Prostate Cancer Cells: Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition

https://pharmaceuticalintelligence.com/2012/11/30/histone-deacetylase-inhibitors-induce-epithelial-to-mesenchymal-transition-in-prostate-cancer-cells/

Williams, S.J. October 31, 2012. How Mobile Elements in “Junk” DNA Promote Cancer – Part 1: Transposon-mediated Tumorigenesis

https://pharmaceuticalintelligence.com/2012/10/31/how-mobile-elements-in-junk-dna-prote-cacner-part1-transposon-mediated-tumorigenesis/

Williams, S.J., reporter, June 19, 2014. Second Annual Single-Cell Sequencing of Cancer Rountable August 20,21, 2014 Washington DC

https://pharmaceuticalintelligence.com/2014/06/19/second-annual-single-cell-sequencing-of-cancer-rountable-august-2021-2014-washington-dc/

Williams, S.J. March 27, 2013. Ethical Concerns in Personalized Medicine: BRCA1/2 Testing in Minors and Communication of Breast Cancer Risk

https://pharmaceuticalintelligence.com/2013/03/27/ethical-concerns-in-personalized-medicine-brca12-testing-in-minors-and-communication-of-breast-cancer-risk/

 

Toxicology

 

Williams, S.J. November 20, 2012. FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules

https://pharmaceuticalintelligence.com/2012/11/20/fda-guidelines-for-developmental-and-reproductive-toxicology-dart-studies-for-small-molecules/

Williams, S.J. November 7, 2012. Report on the Fall Mid-Atlantic Society of Toxicology Meeting “Reproductive Toxicology of Biologics: Challenges and Considerations:

https://pharmaceuticalintelligence.com/2012/11/07/report-on-the-fall-mid-atlantic-society-of-toxicology-meeting-reproductive-toxicology-of-biologics-challenges-and-considerations/

Williams, S.J. October 29, 2013. Heroes in Medical Research: Dr. Carmine Paul Bianchi Pharmacologist, Leader, and Mentor

https://pharmaceuticalintelligence.com/2013/10/29/heroes-in-medical-research-dr-carmine-paul-bianchi-pharmacologist-leader-and-mentor/

Williams, S.J. February 24, 2013. Mobilizing Scientific Societies: Editorial by Science Editor-in-Chief Dr. Bruce Alberts

https://pharmaceuticalintelligence.com/2013/02/24/drl-invests-in-projects-to-improve-the-effectiveness-of-stem-learning-for-people-of-all-ages-its-mission-includes-promoting-innovative-research-development-and-evaluation-of-learning-and-teaching-a/

Williams, S.J. September 24, 2012. Nitric Oxide Covalent Modifications: A Putative Therapeutic Target?

https://pharmaceuticalintelligence.com/2012/09/24/nitric-oxide-covalent-modifications-a-putative-therapeutic-target/ 

Williams, S.J. May 14, 2014. The Bioscience Crowdfunding Environment: The Bigger Better VC?

https://pharmaceuticalintelligence.com/2014/05/14/the-bioscience-crowdfunding-environment-the-bigger-better-vc/

Williams, S.J. February 24, 2014. Tycho Brahe, where art thou? Today’s Renaissance of the Self-Funded Scientist!

https://pharmaceuticalintelligence.com/2014/02/24/tycho-brahe-where-art-thou-todays-renaissance-of-the-self-funded-scientist/

Williams, S.J. May 15, 2013. Finding the Genetic Links in Common Disease: Caveats of Whole Genome Sequencing Studies

https://pharmaceuticalintelligence.com/2013/05/15/finding-the-genetic-links-in-common-disease-caveats-of-whole-genome-sequencing-studies/

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,254 other subscribers
  • Recent Posts

    • Press Release for Five Bilingual BioMed e-Series January 29, 2023
    • 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
    • Verily announced other organizational changes, 1/13/2023 January 16, 2023
    • Mission 4: Use of Systems Biology for Design of inhibitor of Galectins as Cancer Therapeutic – Strategy and Software December 13, 2022
    • Science Has A Systemic Problem, Not an Innovation Problem December 12, 2022
    • Chemistry Nobelist Carolyn Bertozzi’s years at UC Berkeley October 24, 2022
    • Technion #1 in Europe in Field of AI for 2nd Straight Year October 20, 2022
    • Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners October 11, 2022
    • The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells October 11, 2022
    • Cancer Policy Related News from Washington DC and New NCI Appointments October 4, 2022
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


 

Loading Comments...
 

    %d bloggers like this: